Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Nom du journal : Int J Gynecol Cancer
Année : 2024
Volume : 34
Page de départ : 550-558
